In ₹ Crore except Per Share Latest Annual | CIPLA FY26 | SUNPHARMA FY26 | DRREDDY FY26 | LUPIN FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 28.61× | 38.70× | 22.63× | ◆ 17.76× | 22.63× +26% | |
| P/B | 3.22× | 5.29× | ◆ 2.49× | 4.21× | 4.21× -24% | |
| EV/EBITDA | 17.43× | 23.53× | 14.91× | ◆ 10.55× | 14.91× +17% | |
| Market Cap | ₹1.11L Cr | ₹4.44L Cr | ₹95,274 Cr | ₹94,823 Cr | ₹95,274 Cr +16% | |
| Growth | ||||||
| Revenue CAGR 3Y | 7.37% | 10.03% | 10.96% | ◆ 18.88% | 10.96% -33% | |
| Revenue CAGR 5Y | 8.01% | 11.78% | 12.09% | ◆ 13.02% | 12.09% -34% | |
| Net Income CAGR 3Y | 10.88% | 10.57% | -2.66% | ◆ 128.70% | 10.57% +3% | |
| Revenue YoY (latest Q) | 2.33% | 10.46% | -5.51% | ◆ 32.04% | 10.46% -78% | |
| Net Income YoY (latest Q) | -39.18% | ◆ 26.53% | -69.10% | 16.01% | 16.01% -345% | |
| Profitability | ||||||
| EBITDA Margin | 20.89% | 30.33% | 19.15% | ◆ 31.53% | 30.33% -31% | |
| Net Income Margin | 13.71% | ◆ 19.69% | 12.34% | 19.16% | 19.16% -28% | |
| Return on Common Equity | 11.24% | 13.69% | 10.98% | ◆ 23.69% | 13.69% -18% | |
| Return on Capital Employed | 13.17% | 17.17% | 10.62% | ◆ 28.94% | 17.17% -23% | |
| Return on Assets | 9.09% | 10.58% | 7.15% | ◆ 13.96% | 10.58% -14% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.01× | 0.05× | 0.16× | 0.26× | 0.16× -94% | |
| Interest Coverage | ◆ 85.90× | 43.65× | 11.76× | 17.12× | 17.12× +402% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹28,163 Cr | ₹58,462 Cr | ₹33,700 Cr | ₹27,958 Cr | ₹33,700 Cr -16% | |
| Net Income | ₹3,862 Cr | ₹11,509 Cr | ₹4,158 Cr | ₹5,355 Cr | ₹5,355 Cr -28% | |
| Total Assets | ₹42,496 Cr | ₹1.09L Cr | ₹58,123 Cr | ₹38,365 Cr | ₹58,123 Cr -27% | |
| EPS | ₹48.03 | ₹47.8 | ₹50.41 | ₹116.75 | ₹50.41 -5% | |
| Book Value per Share | ₹427.34 | ₹349.6 | ₹457.86 | ₹492.42 | ₹457.86 -7% | |